NASDAQ:VYNE VYNE Therapeutics (VYNE) Stock Price, News & Analysis $1.44 -0.45 (-23.67%) As of 12:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About VYNE Therapeutics Stock (NASDAQ:VYNE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get VYNE Therapeutics alerts:Sign Up Key Stats Today's Range$1.28▼$1.5050-Day Range$1.48▼$2.8052-Week Range$1.12▼$4.30Volume1.33 million shsAverage Volume91,455 shsMarket Capitalization$21.83 millionP/E RatioN/ADividend YieldN/APrice Target$6.25Consensus RatingBuy Company OverviewVYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.Read More… VYNE Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreVYNE MarketRank™: VYNE Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 460th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingVYNE Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVYNE Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about VYNE Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for VYNE Therapeutics are expected to decrease in the coming year, from ($0.97) to ($1.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of VYNE Therapeutics is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of VYNE Therapeutics is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVYNE Therapeutics has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about VYNE Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.07% of the float of VYNE Therapeutics has been sold short.Short Interest Ratio / Days to CoverVYNE Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in VYNE Therapeutics has recently decreased by 9.83%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVYNE Therapeutics does not currently pay a dividend.Dividend GrowthVYNE Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.07% of the float of VYNE Therapeutics has been sold short.Short Interest Ratio / Days to CoverVYNE Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in VYNE Therapeutics has recently decreased by 9.83%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for VYNE Therapeutics this week, compared to 1 article on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, VYNE Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.80% of the stock of VYNE Therapeutics is held by insiders.Percentage Held by Institutions83.78% of the stock of VYNE Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about VYNE Therapeutics' insider trading history. Receive VYNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VYNE Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VYNE Stock News HeadlinesVYNE Therapeutics Inc.: VYNE Therapeutics Provides Update on VYN202 ProgramApril 25 at 12:03 PM | finanznachrichten.deVYNE shares tumble after FDA clinical hold on psoriasis drug studyApril 25 at 12:03 PM | za.investing.comCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…April 25, 2025 | Crypto Swap Profits (Ad)FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On HoldApril 25 at 12:03 PM | benzinga.comVYNE Therapeutics Provides Update on VYN202 ProgramApril 25 at 8:00 AM | globenewswire.comArtiva Biotherapeutics, Inc.: Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical OfficerApril 9, 2025 | finanznachrichten.deArtiva Biotherapeutics Names New Chief Medical OfficerApril 8, 2025 | marketwatch.comVYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 20, 2025 | markets.businessinsider.comSee More Headlines VYNE Stock Analysis - Frequently Asked Questions How have VYNE shares performed this year? VYNE Therapeutics' stock was trading at $3.35 at the start of the year. Since then, VYNE stock has decreased by 56.6% and is now trading at $1.4550. View the best growth stocks for 2025 here. How were VYNE Therapeutics' earnings last quarter? VYNE Therapeutics Inc. (NASDAQ:VYNE) issued its quarterly earnings data on Thursday, March, 6th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.03. The firm earned $0.08 million during the quarter, compared to analyst estimates of $0.14 million. VYNE Therapeutics had a negative trailing twelve-month return on equity of 43.73% and a negative net margin of 6,896.55%. When did VYNE Therapeutics' stock split? VYNE Therapeutics shares reverse split before market open on Monday, February 13th 2023. The 1-18 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. How do I buy shares of VYNE Therapeutics? Shares of VYNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of VYNE Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that VYNE Therapeutics investors own include NIO (NIO), Tesla (TSLA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Meta Platforms (META), Allena Pharmaceuticals (ALNA) and NVIDIA (NVDA). Company Calendar Last Earnings3/06/2025Today4/25/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VYNE CIK1566044 Webvynetherapeutics.com Phone(800) 755-7936FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$6.88 High Stock Price Target$8.00 Low Stock Price Target$5.75 Potential Upside/Downside+265.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,450,000.00 Net Margins-6,896.55% Pretax Margin-6,885.19% Return on Equity-43.73% Return on Assets-38.55% Debt Debt-to-Equity RatioN/A Current Ratio5.81 Quick Ratio5.81 Sales & Book Value Annual Sales$501,000.00 Price / Sales57.08 Cash FlowN/A Price / Cash FlowN/A Book Value$6.36 per share Price / Book0.30Miscellaneous Outstanding Shares15,210,000Free Float14,043,000Market Cap$28.59 million OptionableNot Optionable Beta1.37 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:VYNE) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VYNE Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VYNE Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.